Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Resverlogix Announces Participation in Upcoming Conferences

Posted on: 02 Nov 17

CALGARY, Alberta, Nov. 02, 2017 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix” or the "Company") (TSX:RVX) is pleased to announce the Company’s participation in the following upcoming industry conferences.

•  American Society of Nephrology – ASN 2017 Annual Meeting

Location:New Orleans, LA.
Date:November  3rd, 2017
Poster 1:
Analysis of the Plasma Proteome Reveals Dysregulation of Molecular Pathways in Patients with Stage 4 Chronic Kidney Disease
Presentation Time:10:00am - 12:00pm CT
Date:November  4th, 2017
Poster 2:

Apabetalone (RVX-208) Impacts Key Markers and Pathways Associated with Chronic Kidney Disease in Patients with Severe Renal Impairment

Presentation Time:
10:00am - 12:00pm CT
Meeting Link: LINK

•  BIO-Europe 2017

Location:Berlin, Germany.
Date:November 7th, 2017
Presentation Time:4:45pm CEST
Presenting:Mr. Donald McCaffrey, President and Chief Executive Officer
Conference Link:LINK

•  American Heart Association – AHA Scientific Sessions 2017

Location:Anaheim, CA
Date:November 13th, 2017
Apabetalone Downregulates Factors That Promote Vascular Calcification and Contribute to Cardiovascular Events
Presentation Time:10:30am PT
Meeting Link:LINK

About Resverlogix

Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is the first and only BET inhibitor selective for the second bromodomain (BD2) within the BET protein called BRD4. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with high-risk cardiovascular disease (CVD), diabetes mellitus (DM), chronic kidney disease, end-stage renal disease treated with hemodialysis, neurodegenerative disease, Fabry disease, peripheral artery disease and other orphan diseases, while maintaining a well described safety profile. Apabetalone is the only selective BET bromodomain inhibitor in human clinical trials. Apabetalone is currently being studied in a Phase 3 trial, BETonMACE, in high-risk CVD patients with type 2 DM and low high-density lipoprotein (HDL), and is expected to be initiated in a Phase 2a kidney dialysis trial designed to evaluate biomarker changes and safety parameters in up to 30 patients with end-stage renal disease treated with hemodialysis.

Resverlogix common shares trade on the Toronto Stock Exchange (TSX:RVX).

For further information please visit

Follow us on Twitter: @Resverlogix_RVX (, or on our blog at

For further information please contact:

Investor Relations
Phone: 403-254-9252


Last updated on: 02/11/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.